Akero Therapeutics Inc at Bank of America Healthcare Conference Transcript
Hi, my name is Dan Lundquist. Thank you very much for joining the Wednesday events. I'm the healthcare specialist to BofA and very pleased to welcome with me today Kitty Yale from Akero. She's the Chief Development Officer. She does have some presentation slides, so she'll go through those. And then if we have some time, we have some Q&A as well.
All right. Thank you, Kitty.
Thank you. So good morning, everybody. As Dan said, I am Kitty Yale. I am the Chief Development Officer at Akero. And Akero is developing Efruxifermin or for short, we describe it as EFX as a potential best-in-class NASH therapy.
An EFX is a differentiated Fc-FGF21 fusion protein that's been engineered to mimic the balanced biological activity of native FGF21.
The data I am going to share with you today is from our Phase 2a program. And we are pleased that some of the data that we generated in our Phase 2 program is some of the strongest of
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |